Teverelix® Phase 2b Filing Targets High-CV-Risk Prostate Cancer Niche
The underserved patient segment represents an estimated $4 billion annual market opportunity, according to the company.
The underserved patient segment represents an estimated $4 billion annual market opportunity, according to the company.
Type 2 diabetes represents the largest insulin-treated population yet remains among the least served by closed-loop del…
The peer-reviewed findings position continuous EEG monitoring as a clinical decision-making tool in ICU settings — with…
Immunosuppression mechanism under scrutiny as transplant tolerance data edges closer to clinical relevance for metaboli…
Responder analysis from the Phase 2 VIBRANT trial will detail the proportion of CRSwNP patients achieving clinically me…
Content submitted for republication does not meet editorial criteria for functional ingredients, finished formulations,…
Functional News covers ingredients, finished formulations, and regulatory developments in functional foods and nutraceu…
An 11.75% CAGR through 2034 signals that payers and providers are increasingly willing to reimburse nutrition-forward i…
The RMAT designation accelerates development dialogue with FDA — a regulatory milestone operators in the immunology-adj…
The deal signals pharma's growing interest in fibrosis biology that increasingly intersects with hepatoprotective nutra…
The Austin-based biotech's lead candidate targets the DR3 pathway — a mechanism drawing growing interest in immune-medi…
The amendment signals regulatory confidence in next-generation cell therapy manufacturing as solid-tumor CAR-T programs…